Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Nov;40(11):2661–2663. doi: 10.1128/aac.40.11.2661

Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci.

E Fasola 1, S K Spangler 1, L M Ednie 1, M R Jacobs 1, S Bajaksouzian 1, P C Appelbaum 1
PMCID: PMC163597  PMID: 8913486

Abstract

Microdilution MIC testing was used to test the susceptibility of 202 pneumococci to LY 333328 and six other agents. LY 333328 was the most active glycopeptide (MIC at which 90% of the pneumococci were inhibited [MIC90], 0.008 microgram/ml), followed by teicoplanin (MIC90, 0.06 microgram/ml) and vancomycin (MIC90, 0.5 microgram/ml). Rifampin resistance was seen in some penicillin-resistant strains. The MICs of imipenem and ceftriaxone rose with those of penicillin. Time-kill testing confirmed the excellent antipneumococcal activity of LY 333328.

Full Text

The Full Text of this article is available as a PDF (171.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992 Jul;15(1):77–83. doi: 10.1093/clinids/15.1.77. [DOI] [PubMed] [Google Scholar]
  2. Breiman R. F., Butler J. C., Tenover F. C., Elliott J. A., Facklam R. R. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994 Jun 15;271(23):1831–1835. [PubMed] [Google Scholar]
  3. Friedland I. R., McCracken G. H., Jr Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med. 1994 Aug 11;331(6):377–382. doi: 10.1056/NEJM199408113310607. [DOI] [PubMed] [Google Scholar]
  4. Goldstein F. W., Geslin P., Acar J. F. Comparative activity of teicoplanin and vancomycin against 400 penicillin susceptible and resistant Streptococcus pneumoniae. The French Study Group. Eur J Clin Microbiol Infect Dis. 1994 Jan;13(1):33–34. doi: 10.1007/BF02026121. [DOI] [PubMed] [Google Scholar]
  5. Jacobs M. R. Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae. Clin Infect Dis. 1992 Jul;15(1):119–127. doi: 10.1093/clinids/15.1.119. [DOI] [PubMed] [Google Scholar]
  6. Jacobs R. F., Kaplan S. L., Schutze G. E., Dajani A. S., Leggiadro R. J., Rim C. S., Puri S. K. Relationship of MICs to efficacy of cefotaxime in treatment of Streptococcus pneumoniae infections. Antimicrob Agents Chemother. 1996 Apr;40(4):895–898. doi: 10.1128/aac.40.4.895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Klugman K. P., Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Antimicrob Agents Chemother. 1995 May;39(5):1140–1146. doi: 10.1128/aac.39.5.1140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Pankuch G. A., Jacobs M. R., Appelbaum P. C. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother. 1994 Sep;38(9):2065–2072. doi: 10.1128/aac.38.9.2065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. París M. M., Ramilo O., McCracken G. H., Jr Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 1995 Oct;39(10):2171–2175. doi: 10.1128/aac.39.10.2171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Spangler S. K., Jacobs M. R., Appelbaum P. C. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother. 1996 Feb;40(2):481–484. doi: 10.1128/aac.40.2.481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Spangler S. K., Jacobs M. R., Appelbaum P. C. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):856–859. doi: 10.1128/aac.36.4.856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Viladrich P. F., Gudiol F., Liñares J., Pallarés R., Sabaté I., Rufí G., Ariza J. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother. 1991 Dec;35(12):2467–2472. doi: 10.1128/aac.35.12.2467. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES